0000000000144129

AUTHOR

Maria Cristina Vedovati

showing 4 related works from this author

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baselin…

2021

Abstract Introduction Sex and the presence of specific provoking risk factors, along with age, influence the presentation and prognosis of venous thromboembolism (VTE). We investigated the presentation, course and quality of life in women and men with acute VTE classified according to their VTE provoking factors. Methods PREFER in VTE is an international, non-interventional registry of patients with a first episode of acute symptomatic VTE. Baseline provoking factors were classified as follows: major transient, minor transient, active cancer, and none identifiable. The primary outcome was recurrent VTE. Quality of life and treatment satisfaction were secondary outcomes. Results Of 3,455 pat…

Malemedicine.medical_specialtyEpidemiology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceInternal medicineDeep vein thrombosisEpidemiologyInternal MedicineMedicineHumanscardiovascular diseases030212 general & internal medicineFirst episodeSex Characteristicsbusiness.industry10031 Clinic for AngiologyAbsolute risk reductionCancerAnticoagulantsVenous Thromboembolismequipment and suppliesmedicine.diseaseSex specificNeoplasm RecurrenceRisk factorsLocal2724 Internal MedicineQuality of LifeSexFemalePresentation (obstetrics)Neoplasm Recurrence LocalbusinessVenous thromboembolism
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct

Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboem…

2021

Background: The long-term risk for recurrent venous thromboembolism (VTE) during extended anticoagulation for a first unprovoked VTE is uncertain. Objectives: To determine the incidence of recurrent VTE during extended anticoagulation of up to 5 years in patients with a first unprovoked VTE. Methods: MEDLINE, EMBASE, and the Cochrane CENTRAL were searched to identify randomized trials and prospective cohort studies reporting recurrent VTE among patients with a first unprovoked VTE who were to receive anticoagulation for a minimum of six additional months after completing ≥3 months of initial treatment. Unpublished data on number of recurrent VTE and person-years, obtained from authors of in…

Pediatricsmedicine.medical_specialtypulmonary embolismanticoagulant therapy prognosis pulmonary embolism systematic review venous thromboembolism Anticoagulants Humans Prospective Studies Recurrence Risk Factors Pulmonary Embolism Venous Thromboembolismvenous thromboembolismMEDLINE030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineanticoagulant therapy; prognosis; pulmonary embolism; systematic review; venous thromboembolism; Anticoagulants; Humans; Prospective Studies; Recurrence; Risk Factors; Pulmonary Embolism; Venous ThromboembolismRandomized controlled trialsystematic reviewRecurrenceRisk FactorslawHumansMedicineProspective Studies030212 general & internal medicinecardiovascular diseasesProspective cohort studyanticoagulant therapybusiness.industryIncidence (epidemiology)AnticoagulantsHematologymedicine.diseaseequipment and supplies3. Good healthPulmonary embolismLong term riskMeta-analysisprognosisbusinessVenous thromboembolismprognosi
researchProduct

Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and met…

2021

BACKGROUND The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain. PURPOSE To determine the incidence of major bleeding during extended anticoagulation of up to 5 years among patients with a first unprovoked VTE, overall, and in clinically important subgroups. DATA SOURCES MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to 23 July 2021. STUDY SELECTION Randomized controlled trials (RCTs) and prospective cohort studies reporting major bleeding among patients with a first unprovoked VTE who were to receive oral anticoagu…

Oralmedicine.medical_specialtymedicine.drug_classAdministration OralHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawRisk FactorsInternal medicineInternal MedicineMedicineHumansCumulative incidenceAge Factor030212 general & internal medicineProspective cohort study610 Medicine & healthAdministration Oral Age Factors Aged Anticoagulants Hemorrhage Humans Middle Aged Risk Factors Venous ThromboembolismAgedbusiness.industryIncidence (epidemiology)Risk FactorAnticoagulantAge FactorsAnticoagulantsGeneral MedicineVenous ThromboembolismVitamin K antagonistMiddle Aged3. Good healthConcomitantMeta-analysisAdministrationAdministration Oral; Age Factors; Aged; Anticoagulants; Hemorrhage; Humans; Middle Aged; Risk Factors; Venous ThromboembolismbusinessCohort studyHuman
researchProduct